Imagion Biosystems has released “Notice Pursuant to Section 708A(5)(e) of the Corporations Act.”
Read the notice.
Notice Pursuant to Section 708A(5)(e) of the Corporations Act
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.